<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944319</url>
  </required_header>
  <id_info>
    <org_study_id>75505-01</org_study_id>
    <nct_id>NCT01944319</nct_id>
  </id_info>
  <brief_title>Meropenem Dosage Strategy Based on PPK Model</brief_title>
  <official_title>Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingtao Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a
      population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract
      infection patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Subjects:lower respiratory tract infection patients

        -  Study design:randomized control study.The patients in study group will accept meropenem
           therapy with the regimen decided by a software developed from a PPK-PD model. The
           patients in control group will accept meropenem therapy with the regimen decided by
           attending physician.

        -  Primary endpoint: clinical successful rate of meropenem therapy. The clinical efficiency
           of meropenem therapy will be evaluated one week later from stop of meropenem therapy.

        -  Second endpoint: amount of used antibiotics and bacteriological successful rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success Rate</measure>
    <time_frame>One week after antibiotic therapy finished.</time_frame>
    <description>The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy.
Clinical success was defined as cure or improvement of all signs and symptoms caused by the infection and no requirement for additional antibacterial therapy.
Clinical failure was defined as a persistence or worsening of any new clinical sign or symptom, development of any new clinical signs or symptoms of infection, or the requirement for other systemic antimicrobial therapy at the end of meropenem therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Used Antibiotics</measure>
    <time_frame>participants will be followed for the duration of antibiotic therapy, an average of 10 days</time_frame>
    <description>Record the amount of antibiotics usage during antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological Success Rate</measure>
    <time_frame>At the end of meropenem therapy, an average of 10 days.</time_frame>
    <description>The bacterial success or failure will be evaluated at the end of meropenem therapy.
Bacteriological success including eradication and presumed eradication. Bacteriological failure including persistence and presumed persistence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants in control group will accept routine meropenem therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in study group will accept meropenem therapy based on a PPK and PD model.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine meropenem therapy</intervention_name>
    <description>Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Standard care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem therapy based on a PPK and PD model</intervention_name>
    <description>Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Experimental meropenem therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sixty years and older patients hospitalized at the Peking University Third Hospital
             with community-acquired or hospital-acquired lower respiratory tract infection.

          -  Bacilli was idolated from lower respiratory tract specimens within 48 hours prior to
             study enrollment.

          -  The pathogen was sensitive to meropenem.

          -  Received broad-spectrum antibiotic therapy less than 24 hours, or no improvement after
             antibiotic therapy and pathogen was resistant to the used antibiotics.

        Exclusion Criteria:

          -  Had documented hypersensitivity to carbapenems.

          -  More than one pathogenic Gram-negative bacillus was isolated lower respiratory tract
             specimens.

          -  Positive HIV antibody titre.

          -  Had known or suspected tuberculosis or other infections caused by Gram-positive cocci,
             viruses or fungi at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingtao Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Third Hospita</name>
      <address>
        <city>Haidian District</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>October 18, 2015</results_first_submitted>
  <results_first_submitted_qc>January 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2016</results_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Qingtao Zhou</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Infection; Meropenem; Pharmacokinetics; Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Meropenem therapy with regimen routinely decided by attending physician</description>
        </group>
        <group group_id="P2">
          <title>Study Group</title>
          <description>Patients in Study group will accept meropenem therapy based on PPK and PD parameter.
Meropenem therapy based on PPK and PD: Meropenem therapy with regimen decided by a software developed from a PPK model and clinical PD parameter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Meropenem therapy with regimen routinely decided by attending physician</description>
        </group>
        <group group_id="B2">
          <title>Study Group</title>
          <description>Patients in Study group will accept meropenem therapy based on PPK and PD parameter.
Meropenem therapy based on PPK and PD: Meropenem therapy with regimen decided by a software developed from a PPK model and clinical PD parameter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="B2" value="78" lower_limit="76" upper_limit="84"/>
                    <measurement group_id="B3" value="79" lower_limit="76" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Success Rate</title>
        <description>The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy.
Clinical success was defined as cure or improvement of all signs and symptoms caused by the infection and no requirement for additional antibacterial therapy.
Clinical failure was defined as a persistence or worsening of any new clinical sign or symptom, development of any new clinical signs or symptoms of infection, or the requirement for other systemic antimicrobial therapy at the end of meropenem therapy.</description>
        <time_frame>One week after antibiotic therapy finished.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The participants in control group will accept routine meropenem therapy.</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>The participants in stusy group will accept meropenem therapy based on a PPK and PD model.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success Rate</title>
          <description>The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy.
Clinical success was defined as cure or improvement of all signs and symptoms caused by the infection and no requirement for additional antibacterial therapy.
Clinical failure was defined as a persistence or worsening of any new clinical sign or symptom, development of any new clinical signs or symptoms of infection, or the requirement for other systemic antimicrobial therapy at the end of meropenem therapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Used Antibiotics</title>
        <description>Record the amount of antibiotics usage during antibiotic therapy</description>
        <time_frame>participants will be followed for the duration of antibiotic therapy, an average of 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The participants in control group will accept routine meropenem therapy.</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>The participants in study group will accept meropenem therapy based on a PPK and PD model.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Used Antibiotics</title>
          <description>Record the amount of antibiotics usage during antibiotic therapy</description>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="12.0" upper_limit="29.5"/>
                    <measurement group_id="O2" value="15.0" lower_limit="7.5" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacteriological Success Rate</title>
        <description>The bacterial success or failure will be evaluated at the end of meropenem therapy.
Bacteriological success including eradication and presumed eradication. Bacteriological failure including persistence and presumed persistence.</description>
        <time_frame>At the end of meropenem therapy, an average of 10 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The participants in control group will accept routine meropenem therapy.</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>The participants in study group will accept meropenem therapy based on a PPK and PD model.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriological Success Rate</title>
          <description>The bacterial success or failure will be evaluated at the end of meropenem therapy.
Bacteriological success including eradication and presumed eradication. Bacteriological failure including persistence and presumed persistence.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>The participants in control group will accept routine meropenem therapy.</description>
        </group>
        <group group_id="E2">
          <title>Study Group</title>
          <description>The participants in study group will accept meropenem therapy based on a PPK and PD model.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Qingtao ZHOU</name_or_title>
      <organization>Peking University Third Hospital</organization>
      <phone>86-10-82265562</phone>
      <email>zhouqingtaobysy@sina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

